Alys Pharma to focus on immune-based skin treatments

A biotech company, Alys Pharma, will launch with $100mn in seed financing, focusing on immune system-based treatments for skin diseases. Alys aims to become a leader in immuno-dermatology with 14 active R&D programs. The company targets psoriasis, atopic dermatitis, pruritus, and vitiligo. Alys plans to deliver early clinical trial results for seven to 10 skin treatments over the next three years and aims to raise $200mn in a series A round later this year.